'Anti-alcoholism' drug cleared for use in France

April 25, 2012

French health authorities have approved the use of a drug, originally designed to treat nervous spasms, for the treatment of alcoholism on a "case by case" basis.

AFSSAPS, the regulator that authorises drugs, said that while the Baclofen had not been definitively shown to be efficient in the treatment of alcoholism, it had shown "clinical benefits in some patients".

It recommended in a statement that Baclofen -- the lab name for a medication branded as Kemstro, Lioresal and Gablofen -- should be considered on a "case by case" basis.

The history of the drug goes back 50 years. It was originally designed for epilepsy before becoming licensed to treat spasticity, but researchers are now interested in using it to ease alcoholic craving.

Interest was sparked in 2008 by a book, "Le Dernier Verre" (The Last Drink), by cardiologist Olivier Ameisen, who self-treated his alcoholism with high doses of Baclofen.

The AFSSAPS statement came after French doctors said last month that the drug had cleared an important early test. The trial entailed enrolling 132 who were given Baclofen at high doses over a year.

Eighty percent either became abstinent or turned into . By comparison, two drugs that are commonly used to treat alcoholics, naltrexon and , yield a success rate of 20-25 percent.

Side effects included fatigue, drowsiness, insomnia, dizziness and digestive troubles.

Lead researcher Philippe Jaury of the University of Paris-Descartes said the outcome opened the door to one-year clinical trials, expected to start in May, in which 320 alcoholics would be divided into two groups.

One batch will receive Baclofen, progressively building in dosage until the craving symptoms subside, while the others will receive an inactive look-a-like pill, or placebo.

France's health system is paying 750,000 euros ($469,000) of the 1.2-million-euro ($1.45-million) cost of the trial, and an unidentified donor is paying the rest, Jaury told AFP.

The pre-trial study was published in a specialist journal, and Alcoholism.

Explore further: 'Anti-alcoholism' drug clears key test hurdle

Related Stories

'Anti-alcoholism' drug clears key test hurdle

March 20, 2012
A drug designed to treat nervous spasms has cleared an important early test in a project to see whether it can also cure alcoholism, French doctors said on Tuesday.

New clinical trial to examine medication to treat social withdrawal in Fragile X and autism

July 20, 2011
Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug ...

New drug may reduce seizures in epilepsy

April 13, 2011
A new drug called perampanel appears to significantly reduce seizures in people with hard-to-control epilepsy, according to results of the first clinical trial to test the higher 12 mg dose of the drug. The late-breaking ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.